Boldine Activates Intrinsic Apoptotic Pathway in DU-145 Androgen-Independent Prostate Cancer Cell Line
DOI:
https://doi.org/10.30683/1927-7229.2019.08.03Keywords:
Aporphine alkaloid, prostate cancer, DNA damage, Bcl-2 family proteins, heat shock protein 70.Abstract
Prostate cancer is one of the most common forms of cancer in men and continues to be a problem in the developed world. The treatment approaches for androgen-independent prostate cancer are unsatisfactory and the survival of those patients remains poor. Thus, there is a strong demand to develop novel therapeutic agents to treat and prevent this advanced malignancy. The present study evaluated the effect of boldine (2,9-dihydroxy-1,10-dimethoxy-aporphine), an aporphine alkaloid occurs abundantly in the leaves of Boldo (Peumus boldus Molina), on growth and cell death of DU-145 androgen-independent prostate cancer cell line. The cell viability was measured by MTT test and LDH release was used to quantify necrosis cell death. Genomic DNA, caspase-3 activity, expression of cleaved caspase-9, Hsp70, Bcl-2 and Bax proteins were analyzed in order to study the apoptotic process. The results showed that boldine was able to reduce cell viability in the range of 60-240 mM concentrations, and suggest this aporphine alkaloid induces cell death by intrinsic apoptotic pathway that probably involves the down-regulation of heat shock protein 70 (Hsp70). In fact, an increase of caspase-3 enzyme activity and Bax protein expression, in conjunction with the more pronounced decrease in Bcl-2 occurred in DU-145 cells treated with boldine at 60-120 mM concentrations. In addition, caspase-9 was shown to be observably activated. Moreover, boldine such as quercetin, a well-known Hsp70 protein inhibitor, induced a reduction of Hsp70 expression. The hypothesis of apoptosis induction in our experimental conditions was reinforced by a high DNA fragmentation at 60-120 µM concentrations, not correlated to LDH release. The present findings, starting point for further investigation, suggest that boldine structure might be used to design novel derivatives for the developing of potential new drugs for advanced prostate cancer therapy.
References
American Cancer Society. http://www.cancer.org/ (accessed on 27/7/2017).
Stavridi F, Karapanagiotou EM, Syrigos KN. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010; 36(2):122-30. https://doi.org/10.1016/j.ctrv.2009.06.001 DOI: https://doi.org/10.1016/j.ctrv.2009.06.001
Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011; 18(23): 63. https://doi.org/10.1186/1423-0127-18-63 DOI: https://doi.org/10.1186/1423-0127-18-63
Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer? Semin. Oncol 2013; 40(3): 361-74. https://doi.org/10.1053/j.seminoncol.2013.04.015 DOI: https://doi.org/10.1053/j.seminoncol.2013.04.015
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov 2010; 9(7): 513-14. https://doi.org/10.1038/nrd3220 DOI: https://doi.org/10.1038/nrd3220
Sartor O, Pal SK. Abiraterone and its place in the treatment of metastatic crpc. Nat Rev Clin Oncol 2013; 10(1): 6-8. https://doi.org/10.1038/nrclinonc.2012.202 DOI: https://doi.org/10.1038/nrclinonc.2012.202
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138-48. https://doi.org/10.1056/NEJMoa1209096 DOI: https://doi.org/10.1056/NEJMoa1209096
Yakes F M, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B et al. Cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12): 2298-308. https://doi.org/10.1158/1535-7163.MCT-11-0264 DOI: https://doi.org/10.1158/1535-7163.MCT-11-0264
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31(4): 412-19. https://doi.org/10.1200/JCO.2012.45.0494 DOI: https://doi.org/10.1200/JCO.2012.45.0494
Yedjou CG, Mbemi AT, Noubissi F, Tchounwou SS, Tsabang N, Payton M, Miele L, Tchounwou PB. Prostate cancer disparity, chemoprevention, and treatment by specific medicinal plants. Nutrients 2019; 11(2): pii: E336. https://doi.org/10.3390/nu11020336 DOI: https://doi.org/10.3390/nu11020336
Fernández J, Lagos P, Rivera P and Zamorano-Ponce E. Effect of boldo (Peumus boldus Molina) infusion on lipoperoxidation induced by cisplatin in mice liver. Phytother Res 2009; 23(7): 1024-27. https://doi.org/10.1002/ptr.2746 DOI: https://doi.org/10.1002/ptr.2746
O’Brien P, Carrasco-Pozo C, Speisky H. Boldine and its antioxidant or health-promoting properties. Chem Biol Interact 2006; 159(1): 1-17. https://doi.org/10.1016/j.cbi.2005.09.002 DOI: https://doi.org/10.1016/j.cbi.2005.09.002
Si Y-X, Ji S., Wanga W, Fang N-Y, Jin Q-X, Park Y-D, et al. Effects of boldine on tyrosinase: inhibition kinetics and computational simulation. Process Biochem 2013; 48: 152-61. https://doi.org/10.1016/j.procbio.2012.11.001 DOI: https://doi.org/10.1016/j.procbio.2012.11.001
Gerhardt D, Bertola G, Dietrich F, Figueiró F, Zanotto-Filho A, Moreira Fonseca JC, et al. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. Urol Oncol 2014; 32(1):36.e1-9. https://doi.org/10.1016/j.urolonc.2013.02.012 DOI: https://doi.org/10.1016/j.urolonc.2013.02.012
Cardile V, Avola R, Graziano ACE, Piovano M, Russo A. Cytotoxicity of demalonyl thyrsiflorin A, a semisynthetic labdane-derived diterpenoid, to melanoma cells. Toxicol Vitro 2018; 47: 274-80. https://doi.org/10.1016/j.tiv.2017.12.012 DOI: https://doi.org/10.1016/j.tiv.2017.12.012
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72(7): 248-54. https://doi.org/10.1016/0003-2697(76)90527-3 DOI: https://doi.org/10.1016/0003-2697(76)90527-3
Galvano F, Russo A, Cardile V, Galvano G, Vanella A, Renis M. DNA damage in human fibroblasts exposed to fumonisin B(1). Food Chem Toxicol 2002; 40(1): 25-31. https://doi.org/10.1016/S0278-6915(01)00083-7 DOI: https://doi.org/10.1016/S0278-6915(01)00083-7
Russo A, C. Espinoza CL, Caggia S, Garbarino JA, Hugo Pena-Cortes H, Carvajal TM, et al. A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells. Cancer Lett 2012; 326(2): 199-205. https://doi.org/10.1016/j.canlet.2012.08.025 DOI: https://doi.org/10.1016/j.canlet.2012.08.025
Dumont A, Hehner SP, Hofmann TG, Ueffing M, Droge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappa B. Oncogene 1999; 18(3): 747-57. https://doi.org/10.1038/sj.onc.1202325 DOI: https://doi.org/10.1038/sj.onc.1202325
Baigi MG, Brault L, Nequesque A, Beley M, Hilali RE, Gauzere F, et al. Apoptosis/necrosis switch in two different cancer cell lines: influence of benzoquinone and hydrogen peroxide-induced oxidative stress intensity, and glutathione. Toxicol in Vitro 2008; 22(6): 1547-54. https://doi.org/10.1016/j.tiv.2008.06.008 DOI: https://doi.org/10.1016/j.tiv.2008.06.008
Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108(2): 153-64. https://doi.org/10.1016/S0092-8674(02)00625-6 DOI: https://doi.org/10.1016/S0092-8674(02)00625-6
Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9(3): 459-70. https://doi.org/10.1016/S1097-2765(02)00482-3 DOI: https://doi.org/10.1016/S1097-2765(02)00482-3
Ji F, Lv R, Zhao T. A correlation analysis between tumor imaging changes and p‐AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy. Oncol Lett 2017; 14(6): 6749-753. https://doi.org/10.3892/ol.2017.7005 DOI: https://doi.org/10.3892/ol.2017.7005
Kazemi Noureini S, Tanavar F. Boldine, a natural aporphine alkaloid, inhibits telomerase at non-toxic concentrations. Chem Biol Interact 2015; 231(25): 27-34. https://doi.org/10.1016/j.cbi.2015.02.020 DOI: https://doi.org/10.1016/j.cbi.2015.02.020
Gillis NK, McLeod HL. The pharmacogenomics of drug resistance toprotein kinase inhibitors. Drug Resist Updat 2016; 28: 28‐42. https://doi.org/10.1016/j.drup.2016.06.008 DOI: https://doi.org/10.1016/j.drup.2016.06.008
Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014;19(12) 1871‐82. https://doi.org/10.1016/j.drudis.2014.08.006
Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol 2015; 6(22): 205. https://doi.org/10.3389/fphar.2015.00205 DOI: https://doi.org/10.3389/fphar.2015.00205
Basmadjian C, Zhao Q, Bentouhami E, Dejehal A, Nebegil CG, Johnson RA et al. Cancer wars: natural products strike back. Front Chem 2014; 2(1): 20. https://doi.org/10.3389/fchem.2014.00020 DOI: https://doi.org/10.3389/fchem.2014.00020
Paydar M, Kamalidehghan B, Wong YL, Wong WF, Looi CY, Mustafa MR. Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models. Drug Des Dev Ther 2014; 8(6): 719-33. https://doi.org/10.2147/DDDT.S58178 DOI: https://doi.org/10.2147/DDDT.S58178
Nimmanapalli R, Perkins CL, Orlando M, O’Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61(2): 759-63.
Yang S, Mao Y, Zhang H, Xu Y, An J, Huang Z. The chemical biology of apoptosis: Revisited after 17 years. EurJ Med Chem 2019; 177: 63-75. https://doi.org/10.1016/j.ejmech.2019.05.019 DOI: https://doi.org/10.1016/j.ejmech.2019.05.019
Rigg RA, Healy LD, Nowak MS, Mallet J, Thierheimer MLD, Pang J, et al. Heat shock protein 70 regulates platelet integrin activation, granule secretion and aggregation. Am J Physiol Cell Physiol 2016; 310(7): C568-C75. https://doi.org/10.1152/ajpcell.00362.2015 DOI: https://doi.org/10.1152/ajpcell.00362.2015
Ren A, Yan G, You B and Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by Heat Shock Protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008; 68(7): 2266-74. https://doi.org/10.1158/0008-5472.CAN-07-6248 DOI: https://doi.org/10.1158/0008-5472.CAN-07-6248
Garrido C, Brunet M, Didelot C, Zemati Y, Schimitt E, Kroemer G. Heat Shock Proteins 27 and 70 anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5(22): 2592-601. https://doi.org/10.4161/cc.5.22.3448 DOI: https://doi.org/10.4161/cc.5.22.3448
Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction ofapoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994; 54(18): 4952-957.
